These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 33665166)
1. Pretreatment Plasma EBV-DNA Load Guides Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Cancer: A Meta-Analysis. Lai L; Chen X; Zhang C; Chen X; Chen L; Tian G; Zhu X Front Oncol; 2020; 10():610787. PubMed ID: 33665166 [TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis. Zhou R; Zhu J; Chen X; Liu Y; Wang Y; Zhang T Clin Transl Oncol; 2020 Mar; 22(3):429-439. PubMed ID: 31165410 [TBL] [Abstract][Full Text] [Related]
3. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study. Guo SS; Tang LQ; Chen QY; Zhang L; Liu LT; Guo L; Mo HY; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Wang L; Lv X; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ Oncotarget; 2016 May; 7(20):29739-48. PubMed ID: 27105538 [TBL] [Abstract][Full Text] [Related]
4. Association of Chemoradiotherapy Regimens and Survival Among Patients With Nasopharyngeal Carcinoma: A Systematic Review and Meta-analysis. Zhang B; Li MM; Chen WH; Zhao JF; Chen WQ; Dong YH; Gong X; Chen QY; Zhang L; Mo XK; Luo XN; Tian J; Zhang SX JAMA Netw Open; 2019 Oct; 2(10):e1913619. PubMed ID: 31626318 [TBL] [Abstract][Full Text] [Related]
5. Nomogram Predicting the Benefits of Adding Concurrent Chemotherapy to Intensity-Modulated Radiotherapy After Induction Chemotherapy in Stages II-IVb Nasopharyngeal Carcinoma. Liu SL; Sun XS; Lu ZJ; Chen QY; Lin HX; Tang LQ; Bei JX; Guo L; Mai HQ Front Oncol; 2020; 10():539321. PubMed ID: 33240805 [TBL] [Abstract][Full Text] [Related]
6. MRI-based radiomics to compare the survival benefit of induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A multicenter study. Shen H; Yin J; Niu R; Lian Y; Huang Y; Tu C; Liu D; Wang X; Lan X; Yuan X; Zhang J Radiother Oncol; 2022 Jun; 171():107-113. PubMed ID: 35461950 [TBL] [Abstract][Full Text] [Related]
7. Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A systematic review and meta-analysis. Tan TH; Soon YY; Cheo T; Ho F; Wong LC; Tey J; Tham IWK Radiother Oncol; 2018 Oct; 129(1):10-17. PubMed ID: 29555182 [TBL] [Abstract][Full Text] [Related]
8. Induction chemotherapy followed by intensity-modulated radiotherapy versus concurrent chemoradiotherapy in nasopharyngeal carcinoma: A retrospective analysis. He Y; Zhao Z; Wang Y; He J; Chai J; Wei Z; Guan H; Wang J; Liu Z; Li R; Mu X; He L; Peng X Clin Otolaryngol; 2021 Sep; 46(5):976-982. PubMed ID: 33821552 [TBL] [Abstract][Full Text] [Related]
9. A Systematic Review and Meta-Analysis of Studies Comparing Concurrent Chemoradiotherapy With Radiotherapy Alone in the Treatment of Stage II Nasopharyngeal Carcinoma. Xu YC; Chen KH; Liang ZG; Zhu XD Front Oncol; 2022; 12():843675. PubMed ID: 35903695 [TBL] [Abstract][Full Text] [Related]
10. Induction Chemotherapy Plus Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma in Children and Adolescents: A Matched Cohort Analysis. Li Y; Tang LQ; Liu LT; Guo SS; Liang YJ; Sun XS; Tang QN; Bei JX; Tan J; Chen S; Ma J; Zhao C; Chen QY; Mai HQ Cancer Res Treat; 2018 Oct; 50(4):1304-1315. PubMed ID: 29334605 [TBL] [Abstract][Full Text] [Related]
11. The efficacy and toxicity of induction chemotherapy plus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A meta-analysis of randomized controlled trials. Wang P; Zhang M; Ke C; Cai C Medicine (Baltimore); 2020 Mar; 99(10):e19360. PubMed ID: 32150078 [TBL] [Abstract][Full Text] [Related]
12. Individualized induction chemotherapy by pre-treatment plasma Epstein-Barr viral DNA in advanced nasopharyngeal carcinoma. Zhang J; Peng H; Li WF; Zhang Y; Liu LZ; Tian L; Lin AH; Sun Y; Ma J BMC Cancer; 2018 Dec; 18(1):1276. PubMed ID: 30567511 [TBL] [Abstract][Full Text] [Related]
13. Radiotherapy Alone Versus Concurrent or Adjuvant Chemoradiotherapy for Nasopharyngeal Carcinoma Patients with Negative Epstein-Barr Virus DNA after Induction Chemotherapy. Kong F; Pan G; Du C; Hu C; Ying H Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980576 [TBL] [Abstract][Full Text] [Related]
14. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. Yang Q; Cao SM; Guo L; Hua YJ; Huang PY; Zhang XL; Lin M; You R; Zou X; Liu YP; Xie YL; Wang ZQ; Mai HQ; Chen QY; Tang LQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Li JB; Ling L; Guo X; Hong MH; Chen MY Eur J Cancer; 2019 Sep; 119():87-96. PubMed ID: 31425966 [TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Oral Epstein-Barr Virus DNA Load in Locoregionally Advanced Nasopharyngeal Carcinoma. He YQ; Zhou T; Yang DW; Jia YJ; Yuan LL; Zhang WL; Wang TM; Liao Y; Xue WQ; Zhang JB; Zheng XH; Li XZ; Zhang PF; Zhang SD; Hu YZ; Wang F; Cho WC; Ma J; Sun Y; Jia WH Front Mol Biosci; 2021; 8():757644. PubMed ID: 35096963 [No Abstract] [Full Text] [Related]
16. Efficacy of adjuvant chemotherapy/maintenance chemotherapy after induction chemotherapy and concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Experiences of two centers. Tao HY; He F; Shi QY; Liu R; Wang ZL; Du KP; Li JF; Liu H; Lu ZQ; Zhang JJ; Bai YH Cancer Med; 2023 Mar; 12(6):6811-6824. PubMed ID: 36420689 [TBL] [Abstract][Full Text] [Related]
17. The efficacy of induction chemotherapy or adjuvant chemotherapy added to concurrent chemoradiotherapy in T3-4N0-1M0 nasopharyngeal carcinoma: a propensity score-matched analysis. Zhong Q; Luo D; Li X; Du Q; Liang Q; Liu W; Li J; Zhu X Cancer Biol Ther; 2023 Dec; 24(1):2274121. PubMed ID: 37965924 [TBL] [Abstract][Full Text] [Related]
18. The safety and efficacy of gemcitabine and cisplatin (GP)-based induction chemotherapy plus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a meta-analysis. Tang M; Jia Z; Zhang J Eur Arch Otorhinolaryngol; 2022 Mar; 279(3):1561-1572. PubMed ID: 34259896 [TBL] [Abstract][Full Text] [Related]
19. The evaluation of adding induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma: a meta-analysis. Tang M; Jia Z; Zhang J Eur Arch Otorhinolaryngol; 2021 May; 278(5):1545-1558. PubMed ID: 32700235 [TBL] [Abstract][Full Text] [Related]
20. A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. Chen YP; Wang ZX; Chen L; Liu X; Tang LL; Mao YP; Li WF; Lin AH; Sun Y; Ma J Ann Oncol; 2015 Jan; 26(1):205-211. PubMed ID: 25355717 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]